Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy and safety of this combination in a Russian population of patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: Pfizer
• Treatments: Lamivudine; Lamivudine, zidovudine drug combination; Maraviroc; Zidovudine

Criteria

Inclusion Criteria:

• Over 18 years of age.

• R5 HIV infection on screening tropism test.

• Viral load >1,000 copies/mL.

• Never previously treated with anti-HIV medicines.

Exclusion Criteria:

• Previously treated with anti-HIV medicines.

• Hepatitis B co-infection.